# Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

> **NCT07697443** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 306 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TQB3126

## Key facts

- **NCT ID:** NCT07697443
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-08
- **Final completion:** 2030-08
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697443, "Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*